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Summary
In more than a decade of activity the Italian Register of Multi-
ple Endocrine Neoplasias (RINEM = Registro Italiano delle
Neoplasie Endocrine Multiple) made possible to collect both
clinical and genetic data on Italian kindreds affected by Multi-
ple Endocrine Neoplasia type 1 (MEN1) syndrome. Until the
end of the 80thies no data were available for this syndrome in
Italy. The number of cases referred to RINEM has been con-
stantly increasing during the years. Data on 193 subjects, 41
sporadic and 152 familial cases from 44 MEN1 kindreds have
been collected in RINEM. In 12 Italian informative MEN1 kin-
dreds linkage analysis was initially performed before the
cloning of M E N 1 gene. Thirty-two asymptomatic M E N 1 g e n e
carriers have been originally identified and subsequently in 12
of these clinical confirmation within 1 to 3 years from the ge-
netic test have been reported. The RINEM will focus in the fu-
ture on the preparation of a detailed questionnaire on clinical,
genetic and therapeutic approaches to MEN1 in our Country.
KEY WORDS: multiple endocrine neoplasia, clinical management of en -
docrine tumors, hereditary tumors, genetic diagnosis, antioncogene, MEN1.
Introduction
Rare or orphan diseases constitute a heterogeneous group of
extremely infrequent human disorders that have been reported
to approximately affect fewer than 200,000 people in United
States (http://www.raredisease.org/).
Multiple Endocrine Neoplasia type 1 syndrome (MEN1; OMIM
131100) is a complex tumor-predisposing disorder inherited in
an autosomal dominant manner with a high degree of pene-
trance, nearly 100% within 50 years of age. The syndrome ex-
hibits a high grade of clinical variability, also in members from
the same affected family. More than 20 combinations of both
endocrine and nonendocrine tumors have been reported in
MEN1 patients with three endocrine localizations constituting
the “typical” clinical features of this syndrome: multiple tumors
of parathyroid glands (generally all the parathyroid glands), pi-
tuitary adenomas and tumors of the neuroendocrine cells in the
gastroenteropancreatic (GEP) tract. Due to the complexity of
clinical expression a simple definition including all the tumoral
combinations is lacking. Hence, a MEN1 case may be defined
as a case with at least two of the principal MEN-related en-
docrine tumors, while familial form is defined by the presence
of a MEN1 case, as described above, with a first degree rela-
tive showing one of the three characterizing tumors (1). MEN1
syndrome is most commonly diagnosed in the proband during
the fourth or fifth decade of life with a considerable delay from
the age of biochemically detectable onset, because symptoms
are typically delayed for another 5-8 years (1-3). Early recogni-
tion of affected and at risk individuals within kindred is today fa-
cilitated by DNA-testing (1). However, the age of onset of
MEN1 syndrome is extremely variable, ranging from 5 to 65
years, but the onset of the MEN1-associated primary hyper-
parathyroidism and the onset of MEN1-associated gastrinoma
and insulinoma generally anticipate of 3 and 1 decades, re-
spectively, the onset of the corresponding sporadic counter-
parts. Gastrinomas and carcinoids represent the more frequent
causes of mortality in MEN1 patients. In Table I MEN1-associ-
ated tumors and their prevalence are described.
Advances in molecular biology and genetics have led to the
identification of specific genetic defect that improves the under-
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Table I - MEN1-related endocrine tumours and their prevalence.
Parathyroid adenomas (90%)
GEP Gastrinoma (40%)
Insulinoma (10%)
Others (VIPoma, PPoma, SSoma, gluca-
gonoma) (2%)
Non-functioning (20%)
Anterior pituitary Functioning PRLoma (20%),
GH-, GH/PRL-, TSH-, ACTH-secreting,
or non-functioning  (17%)
Foregut carcinoids Thymic (2%)
Bronchial (2%)
Gastric (ECLoma) (10%)
Adrenal gland Non functioning (20%)
Cutaneous tumors Lipomas (they could be also visceral) (30%)
Facial angiofibromas (85%)
Collagenomas (70%)
Central Nervous SystemMeningiomas (5%)
Ependymomas (1%)
Others Leyomiomas (10%) 
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standing and ability to diagnose this syndrome. Particularly, af-
ter the cloning of MEN1 gene the early detection of asympto-
matic carriers dramatically decreases the morbidity and mortal-
ity of MEN1, providing the opportunity to initiate appropriate
treatment at early stages. Paradoxically, the consequently
longer life span may result in a rising cumulative morbidity and
mortality from MEN1-associated malignancies. Unfortunately,
the lack of genotype/phenotype correlation makes difficult the
use of genetic information to predict clinical behavior, localiza-
tion, early detection and prognosis of related tumors. 
MEN1 gene
The responsible gene, MEN1, mapped to chromosome 11q12-
13 region by combining linkage and tumoral microdeletion analy-
ses and proposed as a tumor suppressor gene (4), has been
cloned in 1997 (5). Its mutations, such as in-frame deletions,
frame-shifts, missense and nonsense mutations, have been de-
scribed at germline level in many of MEN1 affected kindreds (5),
supporting its proposed oncosoppressor nature. At the present,
more than 300 somatic MEN1 mutations have been reported in
literature. M E N 1 is a tumor suppressor gene encoding a 610
amino acid protein named menin that does not reveal homology
to any of the already known human proteins (5, 6). Recent ad-
vances on pathophysiological roles of menin disclose the exis-
tence of an intricate network composed by several molecular
partners interacting with menin: JUND (7), Smad1, Smad3,
Smad5, Runx2 (8), Sin3a, HDAC (9), Pem (10), COMPASS-like
complex, RPA2 (11), FANCD2 (12)., Hsp70, CHIP (13), Hox
(14), TGFb (15), GFAP, vimentin (16), NF-kB (17), NM23H1
(18), ERK, JUNK, Elk-1 and c-Fos (19). However, it is still com-
pletely unknown how mutations in menin cause tumorigenesis,
nor is the function of menin. Menin, mainly located in the nucleus
(20), is widely expressed and may play different roles in different
tissues and probably involved in the regulation of several cell
functions, including DNA replication and repair and transcription-
al machinery and so forth.
Italian background
In Italy neither clinical nor numerical data were available for
MEN1 until the end of the 80thies. For this purpose, in 1991, the
RINEM was established within the activities of the Study Group
on Multiple Endocrine Neoplasia Syndromes of the Italian Soci-
ety of Endocrinology. RINEM collects clinical records on Multiple
Endocrine Neoplasia syndromes obtained from several Italian
Clinical Centers1 by compilation of a simple questionnaire. We
noted a constantly increasing number of cases referred to
RINEM during the years. The primary goal of this initiative was
represented by the collection of both elementary clinical data
and number of affected patients and the eventual geographic
distribution of both MEN syndromes in our Country. However, as
these affected subjects are not representative of whole Italian
population both incidence and prevalence of these syndromes
cannot be obtained by such a survey.
In particular, 44 MEN1 kindreds, 41 sporadic MEN1 cases
have been reported to RINEM. A total of 193 subjects (152 fa-
milial and 41 sporadic cases) have been referred. Linkage
analysis (before M E N 1 gene cloning) and subsequent muta-
tional analysis of MEN1 gene have been performed in our Lab-
oratory for several of the referred MEN1 cases, after obtaining
a signed informed consent by each subject.
Materials and methods
Questionnaires
A very simple questionnaire (Figure 1), specific for the syn-
drome, has been used in order to collect an as large as pos-
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1 Participating Centers to the activity of the RINEM1: Department of Internal Medicine and Clinical Pathophysiology, University of Florence, Florence; University
of Ferrara, Ferrara; Borgo Trento Hospital, Verona; Institute of Endocrine Sciences, University of Milan, Milan. Institute of II Clinica Medica, Policlinico Umberto
I, Roma; Department of Medicina Interna, University of Turin, Turin; Department of Internal Medicine, University of Bologna, Bologna; Department of Medicina
Interna and Endocrine and Metabolic Sciences, University of Perugia, Perugia; Division of Medicina Interna, Lanciano Hospital, Lanciano, Chieti; Institute of
Pathological Anatomy and Histopathology, University of Turin, Turin; Institute of Pathology, University of Parma, Parma; and Surgical Pathology Units,
I.R.C.C.S. San Raffaele, Milan; DISEM, Ospedale San Martino, Genova; Department of Molecular and Clinical Endocrinology and Oncology, Federico II Univer-
sity, Naples, Italy.
Figure 1 - The simple questionnaire used to collect MEN1 cases at RINEM.
Family ID 
(Name/
Number) 
Patient code Degree of 
relationship 
Date of birth Eventual
death
(when, why) 
GEP Pituitary Parathyroids Other tissues
and/or 
diseases 
Genetic test
(Yes/No)
Mutation 
©
 C
IC
 E
DI
ZI
ON
I I
NT
ER
NA
ZI
ON
AL
I
sible number of MEN1 cases without need of a time-consum-
ing compilation by collaborating physicians. MEN1 patients
were registered in RINEM, as individual cases with well-doc-
umented clinical features or as hereditary cases (kindreds
with at least two affected members), according to the above-
described criteria. However, even if each referring physician
strictly respected the clinical diagnostic criteria, we cannot
exclude the possibility of having MEN1 phenocopies record-
ed as MEN1 cases. A MEN1 phenocopy resembles MEN1
but is not caused by ME N 1 mutation (1). Thus some families
might have mutation in other genes, including C a S R for Fa-
milial Hypercalcemia Hypocalciuria (FHH) disorder (21) and
the gene for the Hyperparathyroidism-Jaw Tumor (HPT-JT)
syndrome (22). 
MEN1 Linkage analysis
We performed linkage test in MEN1 kindreds until 1997 when
MEN1 gene was identified (5) and then mutational test has
been introduced. For MEN1 linkage analysis DNA was pre-
pared from at least two affected members, not affected first-de-
gree relatives and corresponding partners of affected subjects
for each kindred in order to identify asymptomatic carriers (23).
Highly polymorphic DNA markers from 11q12-13 region, har-
boring M E N 1 gene, have been used to perform this genetic
analysis (24-26), spanning an interval of 14 cM in this region.
For the analysis, two polymorphic markers exhibited recombi-
nation 0 with the ME N 1 locus and flanking both sides of the
MEN1 gene have been chosen. The diagnostic accuracy to un-
ravel an asymptomatic carrier can reach 99.5% when at least 3
DNA markers, two flanking on each side and one with recombi-
nation 0, result to be informative.
The identification of the MEN1 gene (5) allowed to replace link-
age analysis with mutational analysis in affected families. Link-
age analysis can be still carried out in those familial cases in
which mutational analysis failed to detect mutations within the
coding region of the gene. Currently, in informative kindreds we
use six polymorphic microsatellite markers flanking the MEN1
locus at 11q13: cen-PYGM, D11S4946, D11S4940, D11S4938
and D11S4937, D11S449. The localization and order of all
markers is based on the information presented in the Genome
Database (www.gdb.org). 
MEN1 Mutational analysis
The positional cloning of the M E N 1 gene in 1997 (5) made
possible to perform mutational analysis of coding region and
exon-intron junctions of the gene in both single subjects and fa-
milial cases. Consequently, the identification of an apparently
sporadic form as the first case of a new MEN1 kindred has be-
come easier.
All steps of such analysis, from gene amplification protocols to
DNA sequencing, have been already accurately reported in lit-
erature (27). This method allows the identification of MEN1 mu-
tation carriers. Nevertheless, from 5% to 10% of MEN1 pa-
tients may not harbor mutations in the coding region of the
M E N 1 gene (5, 28-32) but these individuals may have muta-
tions in the promoter or untranslated regions (UTRs), which still
remain to be investigated.
Genomic DNA from peripheral blood leukocytes is used to in-
vestigate coding region (exon 2-10) and exon-intron junctions
of the M E N 1 gene. Each exon is amplified by Polymerase
Chain Reaction (PCR) and an aliquot of each PCR product is
sequenced, both in forward and reverse directions. Sequences
are analyzed on the ABI Prism 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA) and then compared to wild
type reference sequence of the MEN1 gene (U93237). 
Results
MEN1: Clinical and numerical data
Data on a total of 193 subjects (152 familial and 41 sporadic cas-
es) are available. The age range is 8-71 years and the female to
male ratio is 1.2. Total affected subjects were 173, 132 of which
were familial cases. Initially, the asymptomatic carriers at the
time of the report to RINEM were 32. They are now 20 (12 have
been lately report to clinically express the syndrome).
The distribution of typical anatomic sites is reported in Figure 2.
The distribution of non-classical endocrinopathies, of non-en-
docrine tumors and of other clinical entities has been included
in the analysis (Figures 3 and 4, and Table II). The referred
causes of death of MEN1 patients are reported on Table III and
they are aligned with already reported in literature.
Forty-four MEN1 kindreds were registered in RINEM. No differ-
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Figure 2 - Distribution of “typical” anatomic sites involved in MEN1. A
comparison between the French-Belgium Multicentric study (ref. 33)
and RINEM.
Figure 3 - Distribution of “typical” endocrinopathies in familial and spo-
radic MEN1 cases referred to RINEM.
Figure 4 - Distribution of other endocrinopathies in familial and sporadic
MEN1 cases referred to RINEM.
Anterior Pituitary GEP Parathyroid
Anterior
pituitary
GEP
Parathyroids
Early menopause
Adrenal gland
tumors*
Carcinoids
Diabetes
Thyroid disease©
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ences among sexes have been described, according to an auto-
somal pattern of inheritance. The involvement of typical anatom-
ic sites (Figure 2) is similar to information from other Countries
(33, 34). Even the distribution of MEN1-associated tumors by
age groups, both in familial and sporadic cases, is similar to oth-
er international surveys. Thus, it has been possible to collect 250
typical MEN1-associated tumors from 173 patients. On the
whole patients over 40 years of age exhibit primary hyper-
parathyroidism (PHPT) in 92% of cases, neuroendocrine neo-
plasms of gastroenteric tract in 65.5% and anterior pituitary tu-
mors in 35%. As in sporadic cases even in familial forms non-
classical endocrinopathies, non-endocrine tumors and other clin-
ical entities were analyzed (Figure 3 and Table II). Of these 152
familial cases, 125 patients are still alive, while 27 are dead be-
cause of different causes (Table III), mainly represented by gas-
trinomas and carcinoids and in sporadic MEN1 cases 38 pa-
tients are alive and 3 died as reported in Table II. 
Genetic analysis of MEN1
Linkage analysis
Before M E N 1 gene cloning, in 12 Italian informative kindreds
out of 14 families collected through the RINEM linkage analysis
of 11q13 region was performed (23). One hundred and sixty-
two subjects were genotyped and of these ones 45 individuals
were affected. Two families resulted to be not informative. Thir-
teen asymptomatic MEN1 carriers were identified and in 10 of
these we had clinical confirmation within 1 to 3 years from the
genetic test. The clinical history of these subjects showed PH-
PT to be the first manifestation (90%), as expected, in all but
one who exhibited a PRL-secreting tumor. Interestingly, by
RINEM we had the opportunity to genetically test a unique
MEN1 kindred whose linkage analysis demonstrated that two
unrelated affected parents generated three affected sons (two
females and one male), with two of them being described as
homozygotes for MEN1 mutation (35, 36).
MEN1 Gene mutational analysis
Mutational analysis of MEN1 gene was performed in 44 Italian
unrelated MEN1 families (including the 14 kindreds previously
described above) and in 41 isolated MEN1 patients, collected
through RINEM. A total of 45 different heterozygous germline
mutations were identified in 40 of 44 (91%) MEN1 families and
in 20 of 41 (49%) cases referred as sporadic MEN1. These dif-
ferent mutations spread across most of the 9 translated exons
and consisted of 9 nonsense, 11 missense, 4 splicing, 6 inser-
tional and 15 deletional frameshift mutations. As reported in lit-
erature (1), 71% of MEN1 gene mutations at RINEM consist of
nonsense and frameshift mutations, Specifically, 21.5% at ex-
on 2, 7% at exon 3, 9% at exon 4/exon 4.intron 4, 1.7% at in-
tron 4-exon 5, 3.5% at exon 6, 9% at exon 7, 5.3% at exon 8,
12.5% at exon 9, and 27% at exon 10. Thus, 61% of MEN1
mutations are prevalently located in the three larger exons (2, 9
and 10) of the gene, similarly to what observed by Kouvaraki et
al. in a clinical series of MEN1 patients recorded at the Ander-
son Cancer Center of the University of Texas (Figure 5) (37).
The failure to detect mutations in all these cases may reflect
large to complete deletion of the gene, or mutation in the
untested parts such as regulatory or untranscribed regions,
which are undetectable by current methods of screening. In
fact, 3 of the 30 kindreds, not previously analyzed by linkage
approach, resulted to be in linkage for polymorphic 11q13 loci
when performed after the lack of mutation detection.
Moreover, some of the cases recorded at RINEM as MEN1
cases, especially sporadic cases, may be MEN1 phenocopies
(21, 31, 38, 39).
The analysis of the clinical features in these families didn’t sug-
gest any correlation between genotype and phenotype. In gen-
eral our data confirm those already published about the appar-
ent lack of genotype-phenotype correlation (27).
Finally, mutational analysis of the above mentioned MEN1 kin-
dred with the two linkage-based defined homozygotes revealed
the presence of a MEN1 mutation only on the maternal side of
pedigree. Thus, these homozygotes have to be considered as
compound heterozygotes (27).
Di cussion
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Table II - Distribution of nonendocrine tumors and other clinical en-
tities in familial and sporadic cases of MEN1.
Familial % Sporadic %
(n. 152 cases) (n. 41 cases)
Lipomas 3.3 7.3
Meningiomas 1.3 –
Basalioma 0.6 2.4
Cutaneous angiofibromas 1.3 4.8
Prostatic tumor 0.6 2.4
Exocrine pancreatic tumor 1.3 2.4
Liver lesions 3.8 2.4
Acoustic neurinoma – 2.4
Retroperitoneal neurofibromatosis 0.6 2.4
Lymphoma(s) 1.3 2.4
Mammary cancer – 2.4
Ovaric cysts – 2.4
Uterine fibromatosis – 7.3
Blood hypertension 3.3 7.3
TBC 1 -
Table III - Causes of death of MEN1 patients referred to RINEM.
Figure 5 - Most of the Italian MEN1 gene mutations reported at RINEM
are located at exons 2, 9 and 10.
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Originally, geneticists predicted the equivalence: known muta-
tion and known protein alteration = genotype-phenotype corre-
lation. As for many other monogenic disorders even for MEN1
syndrome this correlation is incomplete. In fact, phenotypic
variability within families has been described in several
mendelian diseases (40), where the identical mutation is asso-
ciated with a phenotype that may vary in features such as the
age at onset of symptoms and the severity of symptoms. More-
over, intrafamilial phenotypic variability, all of whose members
had the same mutation, suggest that additional genes, inde-
pendently inherited, and/or environmental factors may influ-
ence the clinical expression. This is particularly true for familial
MEN1 syndrome.
Modifying-phenotype factors have suggested in some cases
(41) and may consist of polymorphism in other genes that may
modulate expression and/or function of the candidate protein.
As described above for menin proteins, the primary mutant
gene product is embedded within a highly complex system in
which a multiplex of genetic polymorphisms, additional nonal-
lelic mutations of genes, encoding for both directly or indirectly
correlated molecular partners, and environmental influences,
singularly or combined, might cause the differences among in-
dividuals.
Surprisingly, it is impressive the observation that occasional
mutation does show a reliable correlation with phenotype,
probably because the function of mutant gene product exceeds
a threshold, above which systemic influences cannot compro-
mise the collective operational integration, or, alternatively, be-
low another threshold, beneath which the function of the mu-
tant protein cannot be raised by other variables within the sys-
tem. Between the two thresholds there is an indeterminate
range in which mutant products have a level of residual func-
tion that may be influenced by additional systemic perturba-
tions (41).
Thus, metabolic-control analysis demonstrated that simple
Mendelian traits may substantially behave as complex traits
(42, 43).
Metabolic pathways have a control shared among several
steps, without a single rate-limiting step control, but with more
than one step having significant influence on pathway flux (43).
The activity of the particular steps in the pathway may be influ-
enced by nonallelic polymorphisms and/or additional indepen-
dent mutations or epigenetic influences so that individuals with-
in the population will differ in flux through various steps in the
pathway, determining an incredibly intricate “super-level” of ge-
netic complexity, even if individuals are genetically identical.
Each individual represents a highly complex collection of sys-
tems because of unique genetic and environmental contribu-
tions that may explain the frequent result in phenotypic differ-
ences among patients, even within the same family.
Conclusions
The use of a simple questionnaire made possible to collect in-
formation on a large number of MEN1 cases in Italy, although
MEN1 cases could be overestimated due to unrecognized phe-
nocopies (21, 31, 38, 39). We confirm the existence of both a
clear susceptibility to develop tumors in different types of en-
docrine and nonendocrine tissues and an intrafamilial pheno-
type variability of tumoral combinations in subjects affected by
MEN1 syndrome. However, these results represent the back-
ground for RINEM future efforts, which will focus on the prepa-
ration of a detailed questionnaire on clinical, genetic and thera-
peutic approaches to MEN1 syndrome in our Country. Specific
forms to help physicians to look for others MEN1-associated le-
sions, such as angiomas, angiofibromas, collagenomas and
meningiomas (44), currently underestimated at RINEM, and to
provide a more detailed clinical anamnesis will be prepared.
Th  availability of a detailed clinical file on Italian MEN1 spo-
radic and familial cases will offer the unique possibility to per-
form homogenous prospective studies on both diagnostic and
therapeutic strategies in a large number of patients. In particu-
lar, both basal and follow up clinical data on pituitary tumors
ar  lacking and no information on pharmacological response of
such neoplasms are available. It should be extremely interest-
ing to compare Italian data to the ones from the French-Bel-
gium Multicentric study that reported a pituitary involvement as
the initial manifestation of MEN1 in 17% of individuals and that
pituitary adenomas were significantly more frequent in women
than men (33).
Hopefully, new acquisitions on the genetic bases underlying
MEN1 syndrome will provide clearer explanations on their
pathogenesis extended to the pathogenesis of sporadic tumor
counterparts. In fact, MEN1 gene has been described to be in-
volved also in the tumorigenesis of sporadic forms of the fol-
lowing endocrine neoplasms such as bronchial carcinoids, gas-
trinomas, parathyroid adenomas, and insulinomas (44).
In order to implement the activity of RINEM concrete future de-
velopments will include the setting of a prospective database to
be focused on: a) the bone mineral density variation/year and
the response to pharmacological therapy in not surgically-treat-
ed MEN1-PHPT patients; b) the age-related variation of
parathyroid glands size; c) the prognosis of MEN1-associated
GEP tumors versus sporadic, non MEN1, GEP tumors; d) vari-
ation of gastrin circulating levels under pharmacological treat-
ent; e) variation of circulating levels of prolactin under phar-
macological therapy; f) the age-related variation of pituitary
gland size.
Moreover, activities driving to the establishment of a specific
Internet web site, preparation of guidelines for the clinical man-
agement and genetic counseling of MEN1 patients, and devel-
opment of educational programs for general practitioners and
specialists in Italian Regions that essentially need them will be
foreseen.
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